ADC Manufacturing & CDMO Market is expected to reach USD 10.49 billion by 2031

ADC Manufacturing & CDMO Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the ADC Manufacturing & CDMO Market will expand from USD 5.15 billion in 2026 to USD 10.49 billion in 2031 at a CAGR of 15.3% during the forecast period.

The commercialization of antibody-drug conjugates (ADCs) with impressive clinical and commercial successes, the outsourcing of complex biologics manufacturing activities, and the demand for specialized contract development and manufacturing services (CDMOs) are set to fuel the ADC Manufacturing & CDMO market during the forecast period. With the number of ADC candidates making it through clinical pipelines and regulatory submissions, there is a growing need for integrated manufacturing capabilities, including antibody production, linker synthesis, payload manufacturing, conjugation, fill-finish, and analytical testing.

The improvements in conjugation technologies, handling of high-potency active pharmaceutical ingredients (HPAPI), and scalable manufacturing platforms are enhancing production efficiency and advancing next-generation ADC therapies to commercialization. As more pharmaceutical and biotechnology firms prefer to rely on specialized CDMOs to handle various components of the development process and manage lower capital expenditure, reduce development timelines and access technical expertise, this trend is driving market expansion. Further supportive of the market growth are the investments in dedicated ADC manufacturing facilities, the technologies for process optimization, and regulatory-compliant production infrastructure.

Request a free sample copy or view the report summary: ADC Manufacturing & CDMO Market Report

ADC Manufacturing & CDMO Market Report Highlights

• By Product Type, the monoclonal antibody component segment holds a significant market share owing to its critical role as the targeting backbone of ADC therapeutics. Linker technologies are seeing constant improvements in payload stability and controlled drug release and are seeing strong growth. Growing demand for cytotoxic payloads is fueled by the development of highly potent ADC candidates across a range of oncology indications by pharmaceutical companies.

• Breast, lung, gastric, ovarian and other solid malignancies are the big drivers for solid tumors by indication, as many ADC therapies are in development and commercialization for these indications. Hematologic malignancies will continue to be an important area as the continued success with the use of ADCs in lymphoma, leukemia, and multiple myeloma. The others segment is growing as ADC drug development moves into other therapeutic areas, as well as into rare diseases.

• Process development and clinical-scale manufacturing represent a significant portion by Stage of Development since there are a considerable number of ADC candidates at the preclinical and clinical development stages. Commercial-scale manufacturing is rapidly increasing because, with the growing number of regulatory approvals and product launches, large-scale manufacturing is now needed, and long-term supply contracts are needed.

• Pharmaceutical and biotechnology companies are the largest users of ADCs, with outsourcing activities and growing needs for specialized ADC development and manufacturing skills. Research institutes also play an important role in the early stage of research collaboration, technology development, and translational studies to support ADC innovation.

• The strong presence of the leading biopharmaceutical companies, CDMO service providers, a well-established CDMO segment, advanced manufacturing facilities, and high investment levels in oncology drug development are driving the North America ADC Manufacturing & CDMO market. Biologics manufacturing capacity is solid and the regulatory environment is favorable, and these factors help Europe retain a strong market share. Asia Pacific is projected to see the highest growth rates driven by rising biopharmaceutical investments, growing capacity of CDMOs, lower manufacturing costs, and growth in ADC development in countries like China, Japan, and South Korea.

ADC Manufacturing & CDMO Market Growth Drivers and Restraints

Growth Drivers:

• Growing ADC Pipeline and Regulatory Approvals: The increasing number of ADC candidates moving into clinical development and the number of approvals continues to grow, creating a need for specialized manufacturing services, process development expertise, and commercial-scale production capabilities.

• Rising Outsourcing by Pharmaceutical and Biotechnology Companies: Pharmaceutical and biotechnology companies are outsourcing to specialised CDMOs to gain access to advanced conjugation technologies, HPAPI handling and expertise, regulatory support and scalable manufacturing capacity without capital investment.

Restraints:

• High Manufacturing Complexity and Cost: Specialized facilities, containment systems, advanced analytical capabilities, and highly skilled personnel are needed to produce ADC, which can be an expensive operation with high capital expenses.

• Regulatory and Supply Chain Challenges: The regulatory requirements are very tight and complex technology transfer can lead to manufacturing limitations and slower time to commercialization.

ADC Manufacturing & CDMO Market Key Development

• Investment: March 2026: Fujifilm invested in VALANX Biotech, an Austrian company specializing in site-specific conjugation technology, to further enhance its integrated antibody-drug conjugate (ADC) manufacturing platform, with commercial operations for end-to-end ADC services in Japan slated for 2027.

ADC Manufacturing & CDMO Market Segmentation

Knowledge Sourcing Intelligence has segmented the ADC Manufacturing & CDMO Market by product type, indication, stage of development, end-user, and geography:

ADC Manufacturing & CDMO Market By Product Type

• Monoclonal Antibody Component

• Linker Technology

• Cytotoxic Payload

ADC Manufacturing & CDMO Market By Indication

• Solid Tumor

• Hematologic Malignancies

• Others

ADC Manufacturing & CDMO Market By Stage of Development

• Process Development & Clinical Scale

• Commercial Scale

ADC Manufacturing & CDMO Market By End-User

• Pharmaceutical & Biotechnology Companies

• Research Institutes

ADC Manufacturing & CDMO Market By Region

• North America

  • USA

  • Canada

  • Mexico

• South America

  • Brazil

  • Argentina

  • Others

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Middle East and Africa

  • Saudi Arabia

  • UAE

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

ADC Manufacturing & CDMO Market Key Players

• F. Hoffmann-La Roche Ltd.

• Pfizer Inc.

• AstraZeneca plc

• Daiichi Sankyo Company, Limited

• AbbVie Inc.

• Astellas Pharma Inc.

• ImmunoGen, Inc.

• Lonza Group AG

• Samsung Biologics Co., Ltd.